World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Plowe, Christopher V
    • Other Affiliation: University of Maryland School of Medicine
  • Roper, Cally
    • Other Affiliation: London School of Hygiene and Tropical Medicine
  • Barnwell, John W
    • Other Affiliation: Centers for Disease Control and Prevention
  • Happi, Christian T
    • Other Affiliation: Harvard School of Public Health
  • Joshi, Hema H
    • Other Affiliation: National Institute of Malaria Research
  • Mbacham, Wilfred
    • Other Affiliation: University of Yaounde I
  • Meshnick, Steven R.
    • Affiliation: School of Medicine
  • Mugittu, Kefas
    • Other Affiliation: Ifakara Health Research and Development Centre
  • Naidoo, Inbarani
    • Other Affiliation: Medical Research Council
  • Price, Ric N
    • Other Affiliation: Menzies School of Health Research
  • Shafer, Robert W
    • Other Affiliation: Stanford University Medical Center
  • Sibley, Carol H
    • Other Affiliation: University of Washington
  • Sutherland, Colin J
    • Other Affiliation: London School of Hygiene & Tropical Medicine
  • Zimmerman, Peter A
    • Other Affiliation: Case Western Reserve University
  • Rosenthal, Philip J
    • Other Affiliation: University of California San Francisco
Abstract
  • Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to their potential is that data on the their prevalence is scattered in disparate databases with no linkage to the clinical, in vitro and pharmacokinetic data that are needed to relate the genetic data to relevant phenotypes. The ongoing replacement of older monotherapies for malaria by new, more effective combination therapies presents an opportunity to create an open access database that brings together standardized data on molecular markers of drug resistant malaria from around the world. This paper presents a rationale for creating a global database of molecular markers for drug resistant malaria and for linking it to similar databases containing results from clinical trials of drug efficacy, in vitro studies of drug susceptibility, and pharmacokinetic studies of antimalarial drugs, in a World Antimalarial Resistance Network (WARN). This database will be a global resource, guiding the selection of first line drugs for treating uncomplicated malaria, for preventing malaria in travelers and for intermittent preventive treatment of malaria in pregnant women, infants and other vulnerable groups. Perhaps most important, a global database for molecular markers of drug resistant malaria will accelerate the identification and validation of markers for resistance to artemisinin-based combination therapies and, thereby, potentially prolong the useful therapeutic lives of these important new drugs.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • Christopher V Plowe et al.; licensee BioMed Central Ltd.
License
Journal title
  • Malaria Journal
Journal volume
  • 6
Journal issue
  • 1
Page start
  • 121
Language
  • English
Is the article or chapter peer-reviewed?
  • Yes
ISSN
  • 1475-2875
Bibliographic citation
  • Malaria Journal. 2007 Sep 06;6(1):121
Publisher
  • BioMed Central Ltd
Access right
  • Open Access
Date uploaded
  • July 29, 2016

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 12936_2007_article_426.pdf 2019-05-06 Public Download
file details 12936_2007_426_moesm1_esm.jpeg 2019-05-06 Public Download
file details 12936_2007_426_moesm2_esm.jpeg 2019-05-06 Public Download